After a longstanding collaboration between the firms, Affymetrix announced that it would acquire genotyping company ParAllele BioScience for roughly $120 million in stock. The deal is expected to close sometime this quarter.
David Rockefeller pledged $100 million to Rockefeller University, where he is honorary chairman and life trustee of the university’s board of trustees. The largest gift in the school’s history, the funding will allow the university to expand its efforts in areas such as genomics, according to the university.
Applied Biosystems is leasing its mass spectrometry manufacturing facility to Delphi Medical Systems. The 50,000-square-foot facility handles manufacturing of mass specs, protein sequencers, and peptide and DNA synthesis products, among others.
NCI has approved suggestions to establish a standardization method for the way biomarker data are measured, analyzed, and reported. This comes as part of a five-year plan to revamp its clinical trial program.
Cognia was awarded an SBIR phase IIB grant through the NSF worth $500,000. That money will go toward the company’s core information management system and help researchers connect tools and content.
An initial set of molecular assembly data from the Biomolecular Interaction Network database, known as BIND, was deposited into Entrez Gene last month. The data release was organized by the Blueprint Initiative Asia along with the National Center for Biotechnology Information and the National Library of Medicine.
Naveen Kulkarni is the new CEO at Polyclone Bioservices, and Praveen Rajendra is the new CIO of the same company. Kulkarni comes to Polyclone from SysArris, and Rajendra was previously at software services firm Nitya Technologies.
Indiana’s BioCrossroads, an initiative to help develop the state’s life sciences industry, has gathered $4 million in seed funding to distribute to life science companies in the incubation phase.
Neurome received a phase I SBIR grant worth $200,000 from NIH to develop and validate software targeted at brain imaging in mice. The money will also go toward adapting the software as a display tool for gene expression data.
Toronto’s MetriGenix acquired GeneXP Biosciences, based in Woburn, Mass. The companies are both working on identifying biomarkers through gene expression for various diseases. Michael Cohen, former president of GeneXP, is the new CSO of MetriGenix.
Researchers at Johns Hopkins University School of Medicine will work in conjunction with Orion Genomics to develop a molecular diagnostic test for colon cancer. Researchers hail from the lab of oncology and methylation expert Andy Feinberg, who will study the differences in cancer and normal tissue patterns using Orion’s methylation-detection technology.
Harry Stylli, former CEO of Xencor and founder of CovX Pharmaceuticals and Aurora Biosciences, is the new CEO and president of Sequenom, filling the post left vacant by Toni Schuh.
Georg Casari has joined Oridis Biomed, a developer of therapeutics for liver cancer and metabolic liver disease, as CIO. Casari was previously vice president of informatics at Cellzome and a co-founder of Lion Bioscience.
GeneGo has received a $100,000 phase I SBIR grant from NIGMS to develop computational methods for reconstructing pathways in human diseases. GeneGo plans to develop algorithms to reconstruct condition-specific pathways based on large sets of high-throughput molecular data.
NIDDK plans to provide up to $4 million over five years to support a bioinformatics unit for a consortium of mouse metabolic phenotyping centers. The unit will develop, house, and maintain the websites and databases for the genotyping network.